Cargando…
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Ja...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496468/ https://www.ncbi.nlm.nih.gov/pubmed/32363737 http://dx.doi.org/10.1111/dom.14074 |
_version_ | 1783583103748407296 |
---|---|
author | Birkeland, Kåre I. Bodegard, Johan Eriksson, Jan W. Norhammar, Anna Haller, Hermann Linssen, Gerard C.M. Banerjee, Amitava Thuresson, Marcus Okami, Suguru Garal‐Pantaler, Elena Overbeek, Jetty Mamza, Jil Billy Zhang, Ruiqi Yajima, Toshitaka Komuro, Issei Kadowaki, Takashi |
author_facet | Birkeland, Kåre I. Bodegard, Johan Eriksson, Jan W. Norhammar, Anna Haller, Hermann Linssen, Gerard C.M. Banerjee, Amitava Thuresson, Marcus Okami, Suguru Garal‐Pantaler, Elena Overbeek, Jetty Mamza, Jil Billy Zhang, Ruiqi Yajima, Toshitaka Komuro, Issei Kadowaki, Takashi |
author_sort | Birkeland, Kåre I. |
collection | PubMed |
description | AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD‐free status. RESULTS: Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD‐free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all‐cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75–2.33) and HR 2.05 (95% CI 1.82–2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all‐cause mortality risk: HRs 3.91 (95% CI 3.02–5.07) and 3.14 (95% CI 2.90–3.40), respectively. CONCLUSION: In a large multinational study of >750 000 CVRD‐free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies. |
format | Online Article Text |
id | pubmed-7496468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-74964682020-09-25 Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study Birkeland, Kåre I. Bodegard, Johan Eriksson, Jan W. Norhammar, Anna Haller, Hermann Linssen, Gerard C.M. Banerjee, Amitava Thuresson, Marcus Okami, Suguru Garal‐Pantaler, Elena Overbeek, Jetty Mamza, Jil Billy Zhang, Ruiqi Yajima, Toshitaka Komuro, Issei Kadowaki, Takashi Diabetes Obes Metab Original Articles AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD‐free status. RESULTS: Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD‐free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all‐cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75–2.33) and HR 2.05 (95% CI 1.82–2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all‐cause mortality risk: HRs 3.91 (95% CI 3.02–5.07) and 3.14 (95% CI 2.90–3.40), respectively. CONCLUSION: In a large multinational study of >750 000 CVRD‐free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies. Blackwell Publishing Ltd 2020-06-03 2020-09 /pmc/articles/PMC7496468/ /pubmed/32363737 http://dx.doi.org/10.1111/dom.14074 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Birkeland, Kåre I. Bodegard, Johan Eriksson, Jan W. Norhammar, Anna Haller, Hermann Linssen, Gerard C.M. Banerjee, Amitava Thuresson, Marcus Okami, Suguru Garal‐Pantaler, Elena Overbeek, Jetty Mamza, Jil Billy Zhang, Ruiqi Yajima, Toshitaka Komuro, Issei Kadowaki, Takashi Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title | Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title_full | Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title_fullStr | Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title_full_unstemmed | Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title_short | Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study |
title_sort | heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496468/ https://www.ncbi.nlm.nih.gov/pubmed/32363737 http://dx.doi.org/10.1111/dom.14074 |
work_keys_str_mv | AT birkelandkarei heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT bodegardjohan heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT erikssonjanw heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT norhammaranna heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT hallerhermann heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT linssengerardcm heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT banerjeeamitava heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT thuressonmarcus heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT okamisuguru heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT garalpantalerelena heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT overbeekjetty heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT mamzajilbilly heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT zhangruiqi heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT yajimatoshitaka heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT komuroissei heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy AT kadowakitakashi heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy |